Ajim Tamboli was named Chief Financial Officer of First Tracks Biotherapeutics, Inc. As of November 7, 2026, First Tracks Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 20, 2026, naming 1 appointment (Form 8-K, April 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like First Tracks Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
First Tracks Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-20. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as First Tracks Biotherapeutics, Inc. files it.
Also on the record for First Tracks Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Chen Yu | 8.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 7.2% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Affinity Asset Advisors, LLC | 5.8% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.9% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| April 22, 2026 | Stake report, Schedule 13G, by EcoR1 Capital, LLC | 9.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs First Tracks Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on First Tracks Biotherapeutics, Inc. and the records around it.
First Tracks Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Watch First Tracks Biotherapeutics, Inc.
Get an email when First Tracks Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on First Tracks Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on First Tracks Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on First Tracks Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-20 | In | Chief Financial Officer | 8-K, 2026-04-20 |
Who leads First Tracks Biotherapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Ajim Tamboli, appointed (filed 2026-04-20).
New leaders reset buying decisions — get the Full Report on First Tracks Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at First Tracks Biotherapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at First Tracks Biotherapeutics, Inc.Every change, in the filing's words
Appointed: Ajim Tamboli, Chief Financial Officer
On April 17, 2026, our board of directors appointed Ajim Tamboli as the Chief Financial Officer, effective as of the Spin-Off.
- Non-Employee Director Compensation Our non-employee directors will be entitled to receive cash and equity compensation as provided in our compensation program for non-employee directors.
- Under the program, non-employee directors will be compensated for service on the board of directors as follows: Cash Retainers Each non-employee director will receive an annual cash retainer of $40,000.
- Each non-employee director who serves as the Chair of the board of directors will receive an additional annual cash retainer of $35,000.
- Chairs of the following committees will be entitled to the following applicable additional annual cash retainers: (a) Audit Committee Chair: $20,000; (b) Compensation Committee Chair: $15,000; (c) Nominating and Governance Committee Chair: $10,000; (d) R&D Committee Chair: $15,000; and (e) Transaction Committee Chair: $20,000.
- Equity Grants Each non-employee director will receive a stock option to purchase 14,000 shares of common stock and 5,000 restricted stock units ("RSUs") as well as a prorated annual equity grant.
- Each of our non-employee directors will receive an annual stock option grant each year in January to purchase 7,000 shares of common stock and 2,500 RSUs.
Tools for this story
Each opens in a new tab, filled in for First Tracks Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.